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Abstract
Background: Matrix metalloproteinases (MMPs), a family of Zn2+-dependent endoproteases, have been shown to
act as fine regulators of both health and disease. Limited research revealed that they are essential to maintaining
ocular physiology and inordinate MMP activities have been linked to several neurodegenerative disorders of the
retina, including age-related macular degeneration, proliferative diabetic retinopathy and glaucomatous optic
neuropathies (GONs). Nevertheless, a clear definition of their pathology-exacerbating and/or -resolving actions is
lacking, especially in the context of GONs, as most studies thus far merely focused on expression profiling in human
patients. Therefore, in an initial step towards an improved understanding of MMP functions in the retina, we
studied the spatial expression pattern of MMP-2, -3, -9 and MT1-MMP in the healthy mouse retina.
Methods: The spatial expression pattern of MMP-2, -3, -9 and MT1-MMP was studied in the healthy mouse retina
via immunohistochemical stainings, and immunoreactivity profiles were compared to existing literature. Moreover,
we considered sensitivity and specificity issues with commercially available MMP antibodies via Western blot.
Results: Basal expression of MMP-2,-3, -9 and MT1-MMP was found in the retina of healthy, adult mice. MMP-2
expression was seen in Müller glia, predominantly in their end feet, which is in line with available literature. MMP-3
expression was described for the first time in the retina, and was observed in vesicle-like structures along the radial
fibers of Müller glia. MMP-9 expression, about which still discords exists, was seen in microglia and in a sparse
subset of (apoptosing) RGCs. MT1-MMP localization was for the first time studied in adult mice and was found in
RGC axons and Müller glia, mimicking the MT1-MMP expression pattern seen in rabbits and neonatal mice.
Moreover, one antibody was selected for each MMP, based on its staining pattern in Western blot.
Conclusions: The present MMP immunoreactivity profiles in the mouse retina and validation of MMP antibodies,
can be instrumental to study MMP expression in mouse models of ocular pathologies and to compare these
expression profiles to observations from clinical studies, which would be a first step in the disentanglement of the
exact role MMPs in ocular/retinal diseases.
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Background
Matrix metalloproteinases (MMPs), a family of Zn2
+-dependent proteases, were originally named after their
ability to cleave and remodel the extracellular matrix
(ECM), however, their substrate repertoire has proven to
be much broader, comprising other proteinases, growth
factors, signaling molecules, cell surface receptors, and
even intracellular targets. By proteolytic cleavage, MMPs
modify the structure and activity of these substrates, and
add a complex extra dimension of biological control. As
a result, MMPs and their major endogenous inhibitors
‘tissue inhibitors of metalloproteinases’ (TIMPs) are im-
portant regulatory nodes in the protease web, a complex
network of interactions that regulates protease activities
and determines the functional state of the proteome and
cell activity [1–3]. Deregulated MMP activity is a com-
mon characteristic of many diseases, including neurode-
generative disorders such as glaucoma, multiple
sclerosis, Huntington’s disease, Alzheimer’s disease,
Parkinson’s disease, etc. [4–11]. Nevertheless, despite
their detrimental impact during central nervous system
(CNS) pathology, there is ample evidence corroborating
MMPs as fine regulators of CNS physiology, and well-
balanced MMP activity is instrumental to CNS develop-
ment, plasticity and repair [12–15].
Also in the retina, MMPs, expressed by resident cells,
invading vasculature and inflammatory cells, have been
associated with pathologies that involve matrix degrad-
ation, cell proliferation, neovascularization and inflam-
mation. Briefly, altered MMP activity, often linked to a
disturbed MMP/TIMP ratio, has been observed in cases
of age-related macular degeneration, proliferative dia-
betic retinopathy, glaucomatous optic neuropathies
(GONs), etc. [5, 16, 17]. In proliferative retinopathies,
such as age-related macular degeneration and diabetic
retinopathy, the primary role of MMPs is believed to be
confined to neovascularization, i.e. vessel invasion and
disruption of the blood-retinal barrier, which ultimately
result in retinal degeneration [18–21]. On the other
hand, the causal role of MMPs during the pathogenesis
of GONs is not yet well-understood, albeit a contribu-
tion of MMP-9 to ECM remodeling leading to
detachment-induced retinal ganglion cell (RGC) death
has been put forward [22–24]. Nevertheless, multiple
studies in GON patients and in animal models of spon-
taneous and experimentally induced GONs, have linked
altered MMP expression/activity to GON onset and dis-
ease progression. In addition, patient studies have
pointed out several polymorphisms in MMP genes as
important risk factors for developing GON [25–27].
Altogether, these data have led to the hypothesis that
MMPs might be involved in GON pathogenesis. How-
ever, the majority of investigations has been conducted
in human patients, and limited their focus to
quantitative changes in MMP expression and activity
levels, rather than determining the spatial localization
and function of these proteinases. In addition, interpret-
ation of the available data is compromised by the many
contradictions in the multitude of studies in GON pa-
tients and animal models. This has several reasons, in-
cluding insufficient specificity of techniques for
localization and quantification of MMP expression/activ-
ity, extensive regulation of MMPs at transcriptional,
translational and post-translational level, low samples
sizes and interindividual variability in MMP expression
[28] and the limitations of in vitro and in vivo animal
models. In order to better understand the functional
relevance of altered MMP expression and the exact in-
volvement of these endopeptidases in GON, mechanistic
studies are needed to interpret expression data obtained
in GON patients. A first requisite for the disentangle-
ment of the role of MMPs in GONs, would be to assess
whether MMP expression patterns in animals corres-
pond to what has been observed in humans. Therefore,
in this manuscript, we describe the spatial expression
pattern of MMP-2, -3, -9 and MT1-MMP in the healthy,
adult mouse retina, by means of immunohistochemical
stainings with different MMP antibodies, combined with
double labeling for specific retinal cell markers. In order
to consider sensitivity and specificity issues with MMP
antibodies, two commercially available antibodies for
each MMP were evaluated via Western blot.
Methods
Experimental animals
All studies were conducted in compliance with the
European Communities Council Directive of 22 Septem-
ber 2010 (2010/63/EU) and the Belgian legislation (KB
of 29 May 2013), and were approved by the KU Leuven
institutional ethical committee. Adult (2–3 months) wild
type mice (C57Bl6) were obtained from the university
breeding colony. Animals were kept under a 12/12 h
light–dark cycle and had ad libitum access to food and
water.
Immunohistochemistry on fixed cryosections
Mice were deeply anaesthetized (30 mg/kg sodium pento-
barbital) (Nembutal, Ceva Santé Animale, Libourne,
France) and perfused transcardially with 4 % phosphate-
buffered paraformaldehyde (PFA) and eyes were dissected.
Eyes were postfixed overnight in 4 % PFA, the cornea and
lens were removed, and the remainder posterior segment
of the eye was cryoprotected in a 10 %-20 %-30 % sucrose
series (in 10 mM phosphate-buffered saline (PBS)) and
embedded in Tissue-Tek optimal cutting temperature
medium (Sakura Finetek, Alphen aan den Rijn, The
Netherlands) to make transverse retinal cryosections
(10 μm).
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For immunostaining of MMPs on these cryosections,
antigen retrieval was performed by heating the sections
in citrate buffer (10 mM [pH 6.0]) for 20 minutes at
95C, followed by a 20 minutes cool-down. In case tyra-
mid signal amplification was used, sections were incu-
bated for 20 minutes in 0.3 % hydrogen peroxidase (in
methanol) to saturate endogenous peroxidases. Next,
sections were subjected to a 1 hour blocking step with
20 % pre-immune serum (Life Technologies, Carlsbad,
CA), followed by overnight incubation with the primary
antibody at room temperature (Table 1). Secondary IgG
antibodies were conjugated to biotin (1:300) (Dako,
Glostrup, Denmark) and applied for 45 minutes,
followed by 30 minutes incubation with streptavidin-
horse radish peroxidase (HRP) (1:100) (Perkin-Elmer,
Waltham, MA). Finally, fluorescein isothiocyanate
(FITC) tyramid signal amplification was performed ac-
cording to the manufacturer’s instructions (Perkin-
Elmer). By exception, for immunostaining with the
MT1-MMP antibody RP-3, secondary IgG antibodies
were HRP-conjugated (1:300) (Dako) and applied for
45 minutes, followed by FITC tyramid signal amplifica-
tion. Sections were rinsed with 10 mM Tris-buffered sa-
line (TBS) in between steps, and pre-immune goat
Table 1 Experimental details for immunohistochemical (double) stainings for MMPs/TIMP and retinal cell markers on retinal
cryosections and retinal flatmounts
Primary antibody (dilution) Primary antibody supplier Secondary antibody (dilution)
Immunohistochemical staining for MMPs on retinal cryosections
MMP-2 asc-8835-R (1:200) (ab1) Santa Cruz, Dallas, TX GAR-B (1:300)
ab19167 (1:200) (ab2) Millipore, Billerica, MA GAR-B (1:300)
MMP-3 ab52195 (1:200) (ab3) Abcam, Cambridge, United Kingdom GAR-B (1:100)
sc-6839-R (1:50) (ab4) Santa Cruz, Dallas, TX GAR-B (1:300)
MMP-9 ab58803 (1:100) (ab5) Abcam, Cambridge, United Kingdom GAM-B (1:300)
ab38898 (1:500) (ab6) Abcam, Cambridge, United Kingdom GAR-B (1:300)
MT1-MMP ab53712 (1:200) (ab7) Abcam, Cambridge, United Kingdom GAR-B (1:300)
RP-3 (1:200) (ab8) Triple Point, Forest Grove, OR GAR-HRP (1:300)
TIMP-1 a sc-5538-R (1:100) Santa Cruz, Dallas, TX GAR-B (1:300)
Double staining for MMPs and retinal cell markers on retinal cryosections
MMP-2 ab19167 (1:200) Millipore, Billerica, MA GAR-HRP (1:300)
+ GS MAB302 (1:500) Millipore, Billerica, MA GAM-Alexa (1:200)
MMP-3 sc-6839-R (1:50) Santa Cruz, Dallas, TX GAR-HRP (1:300)
+ Brn3a MAB1585 (1:100) Millipore, Billerica, MA GAM-HRP (1:300)
MMP-3 ab52195 (1:200) Abcam, Cambridge, United Kingdom GAR-HRP (1:300)
+ GS MAB302 (1:500) Millipore, Billerica, MA GAM-Alexa (1:200)
MMP-9 ab58803 (1:100) Abcam, Cambridge, United Kingdom GAM-B (1:300)
+ Iba-1 019-19741 (1:1000) Wako, Osaka, Japan GAR-Alexa (1:200)
MT1-MMP ab53712 (1:200) Abcam, Cambridge, United Kingdom GAR-HRP (1:300)
+ GS MAB302 (1:500) Millipore, Billerica, MA GAM-Alexa (1:200)
MT1-MMP RP-3 (1:200) Triple Point, Forest Grove, OR GAR-HRP (1:300)
+ GS MAB302 (1:500) Millipore, Billerica, MA GAM-Alexa (1:200)
(Double) staining for MMPs and/or retinal cell markers on retinal flatmounts
MMP-9 ab38898 (1:500) Abcam, Cambridge, United Kingdom DAR-B (1:300)
+ Brn3a sc-31984 (1:750) Santa Cruz, Dallas, TX DAG-Alexa (1:200)
MT1-MMP ab53712 (1:200) Abcam, Cambridge, United Kingdom GAR-B (1:300)
+ RT-97 RT-97 (1:200) Developmental Studies Hybridoma Bank, University of Iowa GAM-Alexa (1:200)
MMP-2 sc-8835-R (1:200) Santa Cruz, Dallas, TX GAR-Alexa (1:500)
GFAP Z0334 (1:2000) Dako, Glostrup, Denmark GAR-Alexa (1:500)
GAR goat anti-rabbit IgG, GAM goat anti-mouse IgG, DAR donkey anti-rabbit IgG, DAG donkey anti-goat IgG, −Alexa Alexa fluorophore-conjugated, −B biotin-
conjugated, GS glutamine synthetase
a immunostaining on unfixed cryosections
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serum and antibodies were diluted in 0.5 % blocking so-
lution (Perkin-Elmer) in TBS. 4′,6-diamidino-2-pheny-
lindole (DAPI; 1 μg/ml in PBS) (Applichem, Darmstadt,
Germany) was used as a fluorescent nuclear counter-
staining and sections were mounted using mowiol anti-
fading medium (10 % mowiol 4–88 (Sigma-Aldrich, St.
Louis, MO), 40 % glycerol, 0.1 % 1,4-diazabicyclo-
[2,2,2]-octane in 0.2 M Tris–HCl [pH 8.5]).
For double immunostainings on cryosections, sections
were treated as described above and primary antibodies
were simultaneously applied overnight (Table 1). The
second day, the Alexa 594-conjugated secondary IgG
antibody (1:200) (Life Technologies) was applied to-
gether with the HRP-conjugated secondary IgG antibody
(1:300) for 1 hour, and the FITC tyramid signal amplifi-
cation protocol was continued. Alternatively, the Alexa
594-conjugated secondary IgG antibody (1:200) was ap-
plied together with the biotin-conjugated secondary IgG
antibody (1:300) for 1 hour, followed by 30 minutes in-
cubation with streptavidin-HRP (1:100) and FITC tyra-
mid signal amplification according to the manufacturer’s
instructions. For the double staining of MMP-3 and
Brn3a, by exception, sections were incubated for 45 mi-
nutes with HRP-conjugated anti-rabbit IgG (1:300)
followed by FITC tyramid signal amplification. Next,
after 3 times 5 minutes rinsing with PBS, sections were
incubated for 45 minutes with biotin-conjugated anti-
mouse IgG (1:300), followed by 30 minutes incubation
with streptavidin-HRP (1:100) and cyanine-3 tyramid
signal amplification according to the manufacturer’s in-
structions (Perkin-Elmer). 4′,6-diamidino-2-phenylin-
dole (DAPI; 1 μg/ml in PBS) was used as a fluorescent
nuclear counterstaining and sections were mounted
using mowiol anti-fading medium.
Immunohistochemistry on unfixed cryosections
Mice were deeply anaesthetized (30 mg/kg sodium
pentobarbital) and sacrificed by cervical dislocation. Eyes
were dissected, rinsed in PBS and immediately embed-
ded in Tissue-Tek optimal cutting temperature medium
to make transverse retinal cryosections (10 μm).
Prior to immunostaining of MMP-2 or TIMP-1, with
antibody sc-8835-R or sc-5538-R respectively (Table 1),
unfixed sections were post-fixed for 10 minutes with 4 %
PFA. Next, immunostaining was performed as described
above, with omission of the antigen retrieval step.
Immunohistochemistry on retinal flatmounts
Mice were deeply anaesthetized (30 mg/kg sodium
pentobarbital) and sacrificed by cervical dislocation. Eyes
were fixed for 1 hour in 4 % PFA, retinas were dissected
and flatmounted and again fixed for 1 hour in 4 % PFA.
Prior to immunohistochemistry, retinal flatmounts were
rinsed in PBS with 0.5 % Triton X-100 for 3 times
10 minutes.
For immunostainings on retinal flatmounts, retinas
were frozen for 15 minutes at −80C, before applying the
primary antibod(y)(ies) (Table 1). The next day, for sin-
gle stainings, an Alexa-conjugated secondary IgG anti-
body (1:500) was applied for 2 hours. For double
stainings, the Alexa 594-conjugated secondary IgG anti-
body (1:200) was applied together with the biotin-
conjugated IgG antibody (1:300) for 1 hour, followed by
30 minutes incubation with streptavidin-HRP (1:100)
and FITC tyramid signal amplification. Retinal flat-
mounts were rinsed with PBS with 0.5 % Triton X-100
in between steps, and all antibodies were diluted in PBS
containing 2 % Triton X-100 and 2 % pre-immune goat
or donkey serum (Life Technologies). Retinal flatmounts
were mounted using mowiol anti-fading medium.
Antibodies, dilutions and experimental details are
summarized in Table 1. For all stainings, negative con-
trols were included by omitting the primary antibody
and by replacing the primary antibody with IgG isotype
control antibodies (Life Technologies) in the same dilu-
tion. All images were taken with an inverted confocal
microscope (FV1000, Olympus, Tokyo, Japan) and proc-
essed using FluoViewer 4.0 (Olympus) and Photoshop
CS5 (Adobe, San Jose, CA) software. Figures show repre-
sentative images of at least 3 technical repeats with sam-
ples from minimum 3 mice.
Western blot
Mice were deeply anaesthetized (30 mg/kg sodium
pentobarbital) and sacrificed by cervical dislocation. Ret-
inas were quickly dissected and homogenized in ice-cold
lysis buffer (50 mM Tris–HCl [pH 7.6], 10 mM CaCl2,
150 mM NaCl, 0.05 % Brij-35 (Sigma-Aldrich), 1 %
Triton X-100, 100 μM phenylmethylsulfonylfluoride),
supplemented with EDTA-free proteinase inhibitor cock-
tail (Roche, Basel, Switzerland). For MT1-MMP, a lysis
buffer dedicated to membrane proteins was used, con-
taining 65 mM Tris–HCl and 2 % SDS, supplemented
with EDTA-free proteinase inhibitor cocktail (Roche).
For each sample, one retina was homogenized in 100 μl
lysis buffer. After homogenization, samples were centri-
fuged, supernatant was collected and protein concentra-
tions were measured using Qubit fluorometric
quantitation (Life Technologies).
Retinal homogenates were loaded on 4–12 % SDS-
PAGE and transferred onto a polyvinylidine fluoride or
nitrocellulose membrane (BioRad, Hercules, CA). After
2 hours of blocking with 5 % Amersham Enhanced
Chemiluminescence Blocking Agent (GE Healthcare,
Buckinghamshire, United Kingdom) in TBS, membranes
were incubated overnight at room temperature with the
primary antibodies (Table 2). The next day, membranes
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were incubated for 45 minutes with HRP-labeled
secondary antibody (1:25000) and protein bands were vi-
sualized using a luminol-based enhanced chemilumines-
cence kit (Thermo Scientific, Waltham, MA). Blots were
rinsed in TBS in between steps and all antibodies were
diluted in 5 % Amersham Enhanced Chemiluminescence
Blocking Agent in TBS. Coomassie Blue total protein
stain was performed to confirm equal sample loading,
and densitometric analysis of the protein bands was per-
formed using Image Lab software (BioRad).
Antibodies, dilutions and experimental details are
summarized in Table 2. Recombinant human (rh) MMP-
2 (125 ng) (co-delivered with Amersham MMP-2 Biotrak
Activity Assay, GE Healthcare), rhMMP-3 (0.01 ng)
(ab39306, Abcam, Cambridge, United Kingdom) and
rhMMP-9 (20 ng) (ab39308, Abcam) were loaded as
positive controls. All images were taken with the Chemi-
Doc MP Imaging System (BioRad) and processed using
Image Lab (BioRad) and Photoshop CS5 (Adobe, San
Jose, CA) software. Figures show representative images
of at least 3 technical repeats with samples from mini-
mum 3 mice.
Gelatin zymography
Samples were prepared as described above for Western
blot. Aliquots containing 120 μg of proteins were incu-
bated with 50 μl gelatin-conjugated sepharose beads
(gelatin sepharose 4B, GE Healthcare) in equilibrating
buffer (0.5 M NaCl, 10 mM CaCl2, 0.01 % Tween-20 in
TBS) for 20 minutes at room temperature, for affinity
precipitation. Next, the beads were rinsed twice with
TBS containing 0.5 M NaCl, 10 mM CaCl2 and 0.05 %
Tween-20, and once with TBS containing 10 mM CaCl2
and 0.05 % Tween-20. Finally, gelatinases were eluted
with 20 μl zymogram loading buffer (Novex Tris Glycine
SDS Sample Buffer, Life Technologies) and loaded on a
10 % gelatin gel (Life Technologies) for electrophoresis.
Gels were incubated in 2.5 % Triton-X (in water) for
30 minutes and developed for 2 days at 37C in TBS
containing 10 mM CaCl2 and 1.25 % Triton X-100. After
staining with Coomassie blue (0.5 % in a mixture of
9:9:2 methanol, water and acetic acid) for 3 hours, gels
were destained for 2 hours (in a mixture of 9:9:2 ethanol,
water and acetic acid) and imaged.
Culture medium from HT1080 human firbosarcoma
cells (5 μl), stimulated with microplasmin to activate se-
creted pro-MMP-2 and pro-MMP-9, was loaded as a
control (kind gift from Dr. B. Jonckx). Images were
taken with the ChemiDoc MP Imaging System (BioRad)
and processed using Image Lab (BioRad) and Photoshop
CS5 (Adobe, San Jose, CA) software. Figures show repre-
sentative images of at least 3 technical repeats with sam-
ples from minimum 3 mice.
Results
Immunostaining on mouse retinal cryosections revealed
that all antibodies tested were suited for immunohisto-
chemistry. Moreover, none of the negative controls re-
vealed any artefacts, autofluorescence or nonspecific
staining.
MMP-2 expression in the healthy, adult mouse retina
In order to investigate the expression and localization of
MMP-2, or gelatinase A, two polyclonal rabbit anti-
MMP-2 antibodies were used. According to the manu-
facturer, antibody sc-8835-R (Santa Cruz) (referred to as
ab1) recognizes epitopes near the C-terminus of human
MMP-2, i.e. the hemopexin domain. Antibody AB19167
(Millipore) (referred to as ab2) was generated by
immunization with a synthetic peptide from the second
half of human MMP-2, and therefore recognizes part of
the hemopexin domain, hinge region or (part of ) the
catalytic domain.
Immunohistochemical stainings, with both antibodies
tested (Fig. 1a–c), revealed that Müller glia express
MMP-2 in the adult, healthy mouse retina, as confirmed
via double labeling with glutamine synthetase (Fig. 1b).
Immunostaining for MMP-2 and GFAP on retinal
Table 2 Protocol and experimental details for Western blotting with MMP and TIMP-1 antibodies on retinal homogenates
Primary antibody (dilution) Secondary antibody Blotting membrane Amount of protein loaded
MMP-2 sc-8835-R (1:100) (ab1) GAR-HRP nitrocellulose 20 μg
ab19167 (1:200) (ab2) GAR-HRP nitrocellulose
MMP-3 ab52195 (1:200) (ab3) GAR-HRP nitrocellulose 20 μg
sc-6839-R (1:100) (ab4) GAR-HRP nitrocellulose
MMP-9 ab58803 (1:500) (ab5) GAM-HRP nitrocellulosePVDF 30 μg
ab38898 (1:5000) (ab6) GAR-HRP
MT1-MMP ab53712 (1:1000) (ab7) GAR-HRP PVDF 50 μg
RP-3 (1:5000) (ab8) GAR-HRP PVDF
TIMP-1 sc-5538 (Santa Cruz) GAR-HRP nitrocellulose 15 μg
GAR goat anti-rabbit IgG, GAM goat anti-mouse IgG, PVDF polyvinylidine fluoride
De Groef et al. BMC Ophthalmology  (2015) 15:187 Page 5 of 16
flatmounts excluded expression of MMP-2 by astrocytes
(Fig. 1d-e). With ab1, intense labeling was seen in the
end feet of the Müller cells, forming part of the inner
limiting membrane, in the radial fibers spanning the
entire retina, in the somata in the inner nuclear layer
(INL), and -however more faintly- also in the apical villi.
Immunostaining with antibody ab2 was less intense, but
nevertheless revealed a clear MMP-2 immunopositive
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Fig. 1 Expression of MMP-2 in the healthy adult mouse retina. a Immunostaining with ab1 revealed a macroglial staining pattern for MMP-2 on
retinal sections. b A double staining for glutamine synthetase (GS) disclosed strong MMP-2 expression in the Müller glia end feet (arrow 1), in their
somata (arrow 3) and radial processes spanning the inner retina (arrow 2), as well as a more faint expression in the radial processes spanning the
outer retina (arrow 4) and in the Müller glia villi (arrow 5). c Immunostaining with ab2 was predominantly observed in Müller glia end feet (arrow
1), in their radial processes in the inner retinal layers (arrow 2), and in synaptic sheets in the OPL (arrow 6). Scale bars, 20 μm. d-e Immunostaining
with ab1 on retinal flatmounts revealed that MMP-2 is not expressed by astrocytes, as staining patterns of MMP-2 and GFAP (for astrocytes) were
clearly divergent. Rather, MMP-2 expression at the inner retinal surface was seen in a punctuate organization, suggestive of Müller glia end feet.
Scale bars, 50 μm. f Western blotting on naive retinal tissue lysates (R) with ab1 and ab2 showed that both antibodies recognize the bands
corresponding to pro-MMP-2 (72 kDa) and active MMP-2 (63 kDa), as well as an active MMP-2 fragment (42 kDa) and a 110 kDa band. The 36 kDa
band visualized by ab2 might represent an autocatalytic cleavage fragment of MMP-2. Recombinant human MMP-2 (rh) was loaded as a positive
control. g Gelatin zymography on naive mouse retinal tissue lysates (R) revealed pro-MMP-2 (72 kDa) and pro-MMP-9 (102 kDa), yet no active
gelatinases. Culture medium from HT1080 human firbosarcoma cells (c), containing pro-MMP-9 (92 kDa), active MMP-9 (82 kDa), pro-MMP-2
(72 kDa) and active MMP-2 (63 kDa), was loaded as a positive control.
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signal in the Müller glia end feet and radial fibers in the
inner retinal layers. Of note, upon immunostaining with
antibody ab2, an intense signal was seen in the outer
plexiform layer (OPL) (Fig. 1c). This likely represents la-
beling of the so-called ‘perisynaptic sheets’ of the Müller
cells, responsible for glutamate recycling at the ribbon
synapses between photoreceptor and bipolar/horizontal
cells [29].
Both antibodies revealed a similar pattern of bands
after Western blot on retinal tissue homogenates, al-
though they differentially labeled pro-MMP-2 (72 kDa)
and active MMP-2 (63 kDa). While ab1 suggested that
MMP-2 is predominantly present in its active form, ab2
indicated a constitutive expression of pro-MMP-2 in the
naive retina (Fig. 1f ). Gelatin zymography on the same
retinal lysates indicated that MMP-2 is merely present in
its pro-form, thus corroborating the result obtained with
ab2 (Fig. 1g). Additionally, both antibodies labeled a
prominent 42 kDa band corresponding to the catalytic
domain of MMP-2 [30], as well as a 110 kDa band,
which is described to represent MMP-2 homodimers
and/or MMP-2-TIMP-2 complexes [30, 31] (Fig. 1f ). In
contrast to ab1, ab2 recognized an additional band of
36 kDa, which has been previously suggested to be the
result of autocatalytic cleavage of the N-terminal
propeptide from the 42 kDa MMP-2 fragment [32]
(Fig. 1f, right panel).
MMP-3 expression in the healthy, adult mouse retina
To explore expression and localization of MMP-3, or
stromelysin-1, two antibodies were used: a monoclonal
rabbit anti-MMP-3 antibody (ab52915, Abcam), further
referred to as ab3, and a polyclonal rabbit anti-MMP-3
antibody (sc-6839-R, Santa Cruz), referred to as ab4. For
both antibodies, epitopes were mapped at the C-
terminal region of the human MMP-3, i.e. the hemo-
pexin domain.
Immunolabeling for MMP-3 with ab3 revealed a
diffuse, dotted expression pattern in all layers of the
retina (Fig. 2a). Given the size and distribution of
these immunopositive puncta, in close association
with the radial processes of Müller glia (Fig. 2b), we
suggest that MMP-3 might be present in trafficking
vesicles. Of note, although the intense labeling in the
nerve fiber layer (NFL) likely localized to Müller glia
end feet, expression of MMP-3 in astrocytes cannot
be excluded. In contrast, immunostaining with the
widely used ab4 revealed a distinct MMP-3 expression
pattern and showed labeling in (nearly) all neurons in
the GCL and interneurons in the INL (Fig. 2c). In
the GCL, where immunolabeling was seen in both
Brn3a+ and Brn3a− neurons, this implies that MMP-3
is expressed by both retinal ganglion cells and dis-
placed amacrine cells (Fig. 2c’, arrow a).
On Western blot, ab3 detected both pro-MMP-3
(55 kDa) and active MMP-3 (47 kDa), while ab4 only la-
beled the active form of MMP-3 in retinal homogenates
(Fig. 2d). In addition, ab4 also abundantly labeled bands
with a molecular weight of 28 kDa, 75 kDa and 110 kDa
(Fig. 2d, right panel). Reports depicting a 110 kDa band
on MMP-3 Western blot and casein zymography [33, 34],
along with its theoretical molecular weight of 110 kDa,
suggest that this band might represent MMP-3 homodi-
mers. Comparison of the MMP-3 ab4 Western blot with a
Western blot for TIMP-1 on identical samples (Fig. 2f),
on the other hand, revealed that the 28 kDa band likely
represents free TIMP-1 and the 75 kDa band MMP-3-
TIMP-1 complexes. Moreover, an immunostaining for
TIMP-1 displayed high similarities to the MMP-3 immu-
nostaining with ab4 (Fig. 2e). These findings demonstrate
that ab4 is not specific for MMP-3, and indicate a high de-
gree of cross-reactivity against TIMP-1. Importantly, this
has strong implications on the interpretation of the immu-
nohistochemical staining for MMP-3 with ab4. Indeed,
given the very intense labeling of TIMP-1 (complexes) on
Western blot, it can be expected that the observed immu-
nostaining rather represents TIMP-1, or at least both
TIMP-1 and MMP-3. Of note, a faint 28 kDa band is also
observed on Western blots with ab3, indicating that also
here a slight affinity for TIMP-1 is present (Fig. 2d, left
panel).
MMP-9 expression in the healthy, adult mouse retina
In order to study expression and tissue distribution of
MMP-9, or gelatinase B, two antibodies from Abcam
were tested: a monoclonal mouse anti-MMP-9 antibody
(ab58803), referred to as ab5 in the remaining text, and
a polyclonal rabbit anti-MMP-9 antibody (ab38898), re-
ferred to as ab6. Ab5 recognizes amino acid residues
626–644 of the human MMP-9, which are part of the
hemopexin domain, while ab6 was produced via
immunization with full-length mouse MMP-9.
As evidenced by a double staining with Iba-1, ab5
stained quiescent microglia -sometimes with elaborate
ramifications- present in the inner plexiform layer (IPL),
INL and OPL (Fig. 3a). Correspondingly, ab6 revealed
MMP-9 expression in microglia in the INL, but also la-
beled scarce neurons in the ganglion cell layer (GCL)
(Fig. 3b–c). Subsequent double stainings for MMP-9 and
Brn3a on retinal flatmounts further disclosed that
MMP-9 is indeed expressed by a minority of RGCs in
the adult healthy retina (Fig. 3c), as already described in
literature [35, 36]. Of note, ab5 also labeled RGCs, but
only upon injury when they upregulate their MMP-9 ex-
pression (data not shown). In addition, ab6 also intensely
labeled the inner limiting membrane, however, it re-
mains speculative whether this represents specific
immunolabeling of MMP-9. Indeed, the presence of
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fibronectin-like domains within the catalytic domain of
MMP-9, might be underlying cross-reactivity of ab6 for
this basal lamina constituent (Fig. 3b).
Western blotting on mouse retinal tissue lysates re-
vealed that the healthy, murine retina contains very low
amounts of MMP-9, adding to the difficulties to
accurately discern MMP-9 on Western blot. Neverthe-
less, both antibodies appeared to recognize active mouse
MMP-9 (92 kDa), as well as a 35 kDa band, likely corre-
sponding to an active MMP-9 subspecies resulting from
autocatalytic processing [37] (Fig. 3d). In addition, and
in contrast to ab5, ab6 also detected pro-MMP-9
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Fig. 2 Expression of MMP-3 in the healthy adult mouse retina. a Immunostaining with ab3 revealed a punctate expression pattern in all retinal
layers, with the most prominent expression in the inner retina. b Double labeling for MMP-3 (ab3) and glutamine synthetase (GS) indicated a
close association of these MMP-3-positive structures with the radial processes of Müller glia. c Immunostaining with ab4 revealed MMP-3
expression in neurons in the GCL and INL. No staining at all was seen on negative control sections (insert). c’ The magnification images show a
double staining with Brn3a, indicating that MMP-3 is expressed by Brn3a+ RGCs (arrow a) as well as Brn3a− displaced amacrine cells (arrow b).
Scale bars, 20 μm. d Western blotting on naive retina tissue lysates (R) revealed that both antibodies recognized pro-MMP-3 (55 kDa) and active
MMP-3 (47 kDa). In addition, ab4 also abundantly labeled free TIMP-1 (28 kDa) and MMP-3-TIMP-1 complexes (75 kDa), and a band around
110 kDa. Recombinant human MMP-3 (rh) was loaded as a positive control. e Immunostaining with antibody sc-5538-R showed high TIMP-1
expression in the GCL and more faint expression in the INL and the ECM of both plexiform layers. Scale bar, 20 μm. f Western blotting for TIMP-1
on naive retina tissue lysates (R) revealed 28 kDa unbound TIMP-1, as well as a 75 kDa complex of TIMP-1 and MMP-3.
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(102 kDa) and previously described MMP-9-TIMP-1 and
MMP-9- neutrophil gelatinase B-associated lipocalin
complexes (110–130 kDa) [38–40] (Fig. 3d, right panel).
Ab5 on the other hand labeled a smear of bands with
descending molecular weights from 82 kDa to 30 kDa,
of which the identity is unknown (Fig. 3d, left panel).
Notably, while mouse MMP-9 exists as a 102 kDa pro-
form and a 92 kDa active form, human pro- and active
MMP-9 weight 92 kDa and 82 kDa, respectively.
MT1-MMP expression in the healthy, adult mouse retina
To study the expression pattern of MT1-MMP, or
MMP-14, two polyclonal rabbit anti-MT1-MMP anti-
bodies were evaluated. According to the manufacturers,
antibody ab53712 (Abcam) (referred to as ab7) recog-
nizes the hemopexin domain, more specifically amino
acid residues 471–520 of human MT1-MMP, while
antibody RP-3 (Triple Point) (referred to as ab8) specif-
ically recognizes the catalytic domain of MT1-MMP.
Immunostaining with antibody ab7 in the retina and
optic nerve head of healthy adult mice, disclosed high
MT1-MMP expression in the RGC axon bundles
(Fig. 4a–c), and immunostaining on brain sections also re-
vealed axonal MT1-MMP expression in the optic nerve
and primary retinal target areas in the brain, i.e. the lateral
geniculate nucleus and the superior colliculus (data not
shown). In addition, although at lower levels as compared
to the axonal expression, MT1-MMP immunostaining
was observed in Müller glia, with the highest intensity
seen in the end feet in the GCL and NFL and in the radial
fibers spanning the outer retinal layers (Fig. 4d–f ). Also
ab8 labeled end feet and radial fibers of the Müller cells,
yet it did not label RGC axons (Fig. 4g–h). Of note, MT1-
MMP expression was also observed in the photoreceptors,
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Fig. 3 Expression of MMP-9 in the healthy, adult mouse retina. a Immunostaining with ab5 revealed MMP-9 in resident microglia (arrow 1),
predominantly in the IPL, INL and OPL. The insert clearly shows co-localization of MMP-9 and Iba-1. b Immunostaining with ab6 labeled MMP-9
expression in the small cell bodies of microglia in the INL (arrow 1), but MMP-9 was also found to be expressed in a handful of RGCs (arrow 2). Of
note, the strong immunoreactivity of the inner limiting membrane might be related to the antibody’s affinity for fibronectin-like domains, which
are not only present in MMP-9, but also in the basal lamina of the inner limiting membrane. No staining at all was seen on negative control
sections (insert). c A double staining for MMP-9 (ab6) and Brn3a on a retinal flatmount disclosed MMP-9 expression by a subset of RGCs. Scale
bars, 20 μm. d Western blotting on naive retina tissue lysates (R) with ab5 disclosed active MMP-9 (92 kDa) and an active MMP-9 fragment
(35 kDa). In addition, a series of unknown bands was seen. Western blotting with ab6, revealed both pro-MMP-9 (102 kDa) and active MMP-9
(92 kDa), as well as MMP-9 complexes (110 and 130 kDa) and an active MMP-9 fragment (35 kDa). Recombinant human MMP-9 (rh) was loaded
as a control. Of note, while mouse pro- and active MMP-9 have a molecular weight of 102 kDa and 92 kDa, human pro- and active MMP-9 weigh
92 kDa and 82 kDa, respectively.
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however, while ab7 stained the outer segments, ab8 la-
beled the inner segments.
Western blotting showed that, while both antibodies
recognized soluble, active MT1-MMP (50–53 kDa), only
ab8 labeled membrane-bound, active MT1-MMP
(57 kDa) (Fig. 4i). In addition, both antibodies revealed a
series of bands that represent MT1-MMP subspecies
resulting from autocatalytic and non-autocatalytic pro-
cessing and shedding of 57 kDa MT1-MMP [41]. Ab7
labeled protein bands of 40 kDa (40–44 kDa membrane-
anchored, inactive degradation product), 32 kDa and
27 kDa (27–32 kDa active soluble fragment) (Fig. 4i,
right panel), while ab8 recognized protein bands of
44 kDa, 40 kDa, 32 kDa and 18 kDa (inactive, soluble
fragment) (Fig. 4i, left panel). Of note, it is theoretically
impossible for ab8, which has been designed to
recognize the catalytic domain, to recognize the 40–
44 kDa inactive subspecies of MT1-MMP, as these lack
the catalytic domain. This raises concerns about the spe-
cificity of ab8.
Discussion
In this manuscript, the baseline spatial expression pat-
tern of a selection of MMPs, namely MMP-2, -3, -9 and
MT1-MMP, was investigated in the adult mouse retina.
Immunohistochemistry with commercially available
MMP antibodies was combined with double stainings
with validated antibodies against retinal cell markers, to
identify the cell types that express these MMPs. Experi-
ence has learned that the specificity of antibodies, com-
mercially available or self-made, is not guaranteed.
Therefore, the antibodies were validated by performing
Western blot on retinal tissue lysates and recombinant
MMPs to check for their specificity and sensitivity.
MMP-2 expression in the healthy, adult mouse retina
Both antibodies under study revealed MMP-2 expression
in the Müller glia, although there were differences in the
amount and localization of the staining: while the use of
ab1 resulted in immunostaining of the entire Müller cell,
ab2 only stained the Müller cell compartments in the
inner retinal layers. Likely, MMP-2 expression is more
abundant in the inner retinal layers and the observed
difference reflects a difference in sensitivity between
both antibodies. Moreover, gelatin zymography data in-
dicated that ab2 is likely to more reliably discriminate
between pro-MMP-2 versus active MMP-2 than ab1, as
both gelatin zymography and Western blot with ab2
agree that MMP-2 is present in its pro-form in the naive
retina. Moreover, ab1 performed poorly on PFA-fixed
cryosections so that unfixed cryosections are needed for
good results, which is a major drawback in terms of
histological and morphological quality. As a conse-
quence, we propose ab2 for further studies. Of note,
while there was only faint staining of pro- and active
MMP-2, high molecular weight complexes and low mo-
lecular weight degradation products were abundantly la-
beled on the MMP-2 Western blots, indicating that
there is a high turnover of MMP-2 in the healthy adult
mouse retina.
When comparing these results to what is known about
MMP-2 expression in literature, it turns out that our
present immunohistochemical data largely confirm pre-
vious MMP-2 expression data. The sole publication de-
scribing MMP-2 expression in the mouse retina revealed
MMP-2 immunoreactivity in Müller glia and astrocytes,
in addition to RGCs [42]. In primates, more specifically
in human and macaque monkey, MMP-2 expression was
also detected in RGC somata and in their axons in the
NFL, however no glial expression was observed [43, 44].
Given this very limited amount of data to compare with,
it remains speculative whether MMP-2 expression is to
be expected in RGCs and/or their axons. To answer this
question, the antibody used by Zhang et al. [42] should
be evaluated for specificity, similar to the validation of
the antibodies performed here, and double stainings
should be performed to irrefutably demonstrate expres-
sion by RGCs and astrocytes. Alternative strategies to
study spatial expression patterns of MMP-2, include in
situ hybridization and in situ gelatin zymography. How-
ever, while the first technique is limited to the
visualization of mRNA and thus does not reveal protein
expression nor activity, the second is not specific for
MMP-2 as it visualizes all gelatinolytic activity.
(See figure on previous page.)
Fig. 4 Expression of MT1-MMP in the healthy adult mouse retina. a Immunostaining with ab7 on a flatmounted retina revealed that MT1-MMP is
expressed by all RGC axons. b-c The axonal labeling was confirmed by a double staining for phosphorylated neurofilament heavy (detected with
the RT-97 antibody). Scale bar, 200 μm. d-d’ In addition to this abundant expression by RGC axons, MT1-MMP expression is also seen in the Müller
glia with ab7. Of note, glial expression levels of MT1-MMP are lower than in the axons, and image exposure time was lengthened to reveal this
more faint MT1-MMP expression. e A double staining with glutamine synthetase (GS), confirmed that – besides expression in the axons (arrow 1)
–, ab7 also visualized MT1-MMP expression in Müller glia end feed (arrow 2) and radial processes (arrow 3) and in photoreceptor outer segments
(arrow 4) on retinal sections. Scale bar, 20 μm. f Immunostaining with ab8 confirmed MT1-MMP expression in the Müller glia end feet (arrow 2)
and radial processes (arrow 3) and in photoreceptor inner segments (arrow 4), but did not reveal axonal expression. g-h MT1-MMP expression in
Müller glia was confirmed by a double staining with glutamine synthetase. Scale bar, 20 μm. i Western blotting with antibody ab7 revealed
soluble, active MT1-MMP (50–53 kDa), in addition to several MT1-MMP subspecies (40 kDa, 32 kDa, 27 kDa). Western blotting with ab8 revealed
membrane-bound, active MT1-MMP (57 kDa), as well as soluble, active MT1-MMP (50 kDa) and 44 kDa, 40 kDa, 32 kDa and 18 kDa fragments.
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Current knowledge about the role of MMP-2 in the
healthy versus glaucomatous retina is as sparse as our
knowledge about its expression. MMP-2 activity/expres-
sion was reported to remain unchanged in some reports
[35, 42, 43, 45, 46], while others -although using the
same GON models- revealed increased MMP-2 activity
within the first hours post injury [42, 47]. Based on its
spatial expression pattern described here, one can
hypothesize that MMP-2 might be involved in glial re-
activity upon retinal damage. Nevertheless, MMP-2 defi-
ciency did not protect from RGC death after optic nerve
ligation in mice [23].
MMP-3 expression in the healthy, adult mouse retina
The results obtained via immunohistochemistry with the
two MMP-3 antibodies under study, appeared very con-
tradicting at first sight. Indeed, while ab3 revealed a
macroglial staining pattern, ab4 clearly indicated that
MMP-3 was expressed by neurons. However, an explan-
ation for these puzzling data was found in the Western
blot patterns of the antibodies. Ab3 detected both pro-
MMP-3 and active MMP-3. Ab4, on the contrary,
weakly labeled active mouse MMP-3 but no pro-MMP-
3, yet abundantly labeled protein bands of 28 kDa,
75 kDa and 110 kDa. Remarkably, the protein bands of
28 kDa and 75 kDa were identified as free TIMP-1 and a
MMP-3-TIMP-1 complexes, respectively. Of note, also
ab3 revealed a faint band of 28 kDa, indicating that also
this antibody is not entirely specific for MMP-3 and
might recognize free TIMP-1 as well. In line with these
results, Western blot and immunohistochemistry experi-
ments with these two antibodies in the developing
cerebellum, unveiled a similar discrepant neuronal
versus glial expression pattern, as well as additional
Western blot bands [12].
The limited specificity of the MMP-3 antibodies has
major implications for their use in immunohistochemi-
cal stainings. The use of ab4 resulted in immunolabeling
of displaced amacrine cells and RGCs in the GCL, as
well as interneurons in the INL. However, it can be as-
sumed that TIMP-1 expression, rather than (or in
addition to) MMP-3 expression, was visualized. Ab3 re-
vealed punctate MMP-3-immunopositive structures
along the radial fibers of the Müller glia, and, notwith-
standing its weak affinity for free TIMP-1, seems to be a
reliable antibody to detect MMP-3 protein expression in
the retina. The nature of these presumed vesicles, which
are present throughout all retinal layers but are most
abundant in the inner retina, remains thus far
unidentified.
Limited attention has been devoted to the expression
and function of MMP-3 in the healthy and glaucomat-
ous retina so far. The basal expression pattern of MMP-
3 has not been described yet, although a strong increase
in MMP-3 mRNA expression in the retina of rats sub-
jected to an ocular hypertension GON model or to optic
nerve injury [48–50] suggests MMP-3 to be an import-
ant player during glaucomatous damage. The glial origin
of MMP-3 expression discovered here could indicate the
involvement of MMP-3 in glial reactivity. On the other
hand, the MMP-3 loaded vesicles within the Muller glia
can be transported along the entire retina and therefore
be involved in virtually every pathophysiological process,
not to mention the described pro- and anti-apoptotic ac-
tions of MMP-3 in the CNS [12, 51, 52].
MMP-9 expression in the healthy, adult mouse retina
Despite the striking differences in their Western blots,
a highly similar immunostaining pattern was seen with
the two anti-MMP-9 antibodies under study. Both anti-
bodies indicated that quiescent microglia are the most
important MMP-9-expressing cells in the healthy, adult
mouse retina. In addition, a very limited number of
RGCs was visualized upon immunohistochemical stain-
ing with ab6. Of note, while no MMP-9 expression in
RGCs was seen with antibody ab5 in the naive retina,
abundant RGC staining could be observed in retinas of
mice subjected to a GON model [53]. This is in line
with existing literature, which states that MMP-9 ex-
pression is upregulated in RGCs undergoing apoptosis
[23, 24, 35, 36, 42, 45–47, 54]. As the number of dying
RGCs is almost non-existing in a naive retina and the
expression level of MMP-9 very low, this might be the
reason why there was no RGC immunostaining seen
with antibody ab5, hence indicating that ab5 is likely to
have a lower sensitivity as compared to antibody ab6.
Moreover, ab5 only recognized active mouse MMP-9
on a Western blot, while ab6, designed to recognize
full-length mouse MMP-9, revealed both pro-MMP-9
and active MMP-9.
Remarkably, the use of ab6 for MMP-9 immunostain-
ing also resulted in an intense labeling of the inner limit-
ing membrane. As ab6 was generated by immunization
with full length MMP-9, which includes three contigu-
ous fibronectin type II-like domains within the catalytic
domain, there is a high chance that this is the result of
cross-reactivity of ab6 with fibronectin, one of the major
constituents of the inner limiting membrane. Neverthe-
less, Western blot with ab6 on retinal tissue homoge-
nates indicated that this is a highly specific antibody for
MMP-9, as all protein bands were related to MMP-9
subspecies, complexes and degradation products. The
Western blot with ab5, on the other hand, only revealed
active MMP-9 in the mouse retina, in addition to a
series of protein bands with unknown identity. Notably,
Western blot labeling patterns of MMP pro- and active
subspecies seem not readily translatable between mice
and human samples. As illustrated by this Western blot
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for MMP-9, antibodies recognizing pro- and/or active
MMP in mouse retinal samples do not necessarily also
recognize pro- and/or active recombinant human MMP.
Taken together, based on these Western blot data, ab6
seems to be the most reliable antibody, even despite its
potential affinity for fibronectin.
A multitude of studies, using various rodent models
of GON, have revealed that MMP-9 expression and ac-
tivity in the GCL increases in the glaucomatous retina
[23, 24, 35, 36, 42, 45–47, 54] and that this increased
MMP-9 activity plays a key role in the promotion of
detachment-induced RGC death by interfering with
integrin-mediated survival signaling [24, 36, 55]. Using
one particular antibody for immunohistochemistry, two
studies pointed out reactive astrocytes as the source of
MMP-9 expression, both in the naive and glaucomatous
mouse retina [42, 54], and excluded endothelial cells,
microglia and RGCs [54]. Other studies used in situ
gelatin zymography and immunohistochemistry to
point out that MMP-9 expression is virtually absent in
the naive retina but upregulated in RGCs upon induc-
tion of glaucomatous damage [35, 36]. The findings ob-
tained within this chapter seem to support the latter
theory, although we also revealed MMP-9 expression
by microglia.
MT1-MMP expression in the healthy, adult mouse retina
MT1-MMP is a very complex MMP to investigate. Not
only does this MMP occur in its membrane-bound form,
it also undergoes autocatalytic and non-autocatalytic
processing events, resulting in a series of MT1-MMP
subspecies with varying degrees of activity, which can be
endocytosed from and/or recycled back to the cell sur-
face and shed into the extracellular space [41, 56]. Both
antibodies tested appear to recognize many of these sub-
species, which resulted in very complex Western blot
patterns. Western blotting of retinal tissue homogenates
pointed out that both antibodies labeled the active, sol-
uble form of MT1-MMP (50–53 kDa) that is shed from
the cell membrane upon cleavage in the stem region of
mature MT1-MMP, while the active, membrane-bound
MT1-MMP (mature MT1-MMP, 57 kDa) was only rec-
ognized by ab8. In addition, both antibodies revealed
MT1-MMP processing/shedding products. It is, how-
ever, most clear that they have very different affinities:
while ab7 preferentially labeled soluble MT1-MMP (50–
53 kDa), ab8 most abundantly labeled 27–32 kDa frag-
ments. Notably, these 27–32 kDa subspecies have been
identified as a soluble, catalytically competent products
formed by non-autocatalytic shedding of 57 kDa
membrane-bound MT1-MMP. Due to the complexity
and incomplete overlap of the labeling patterns of both
antibodies, it remains unclear which one is preferable
over the other. While we argue that ab8 may show a lack
of specificity (see above), ab7 does not label membrane-
bound mature MT1-MMP and hence overlooks the
physiologically most relevant MT1-MMP species. The
best choice might be dependent on the scientific ques-
tion to be answered in a certain Western blot or immu-
nohistochemistry experiment.
When applied for immunohistochemistry, both anti-
bodies unequivocally revealed MT1-MMP expression by
Müller glia. MT1-MMP immunostaining was very clear
in the NFL and GCL, where the end feet of the Müller
glia were highly immunoreactive, moreover, ab7 also vi-
sualized MT1-MMP-positive Müller glia radial fibers in
the outer retinal layers. Second, MT1-MMP was also
found in the light-sensitive segments of the photorecep-
tors, namely in the outer segments when stained with
ab7 and in the inner segments when immunolabeled
using ab8. Finally, ab7 intensely labeled RGC axon bun-
dles in the NFL. As it can be assumed, based on the val-
idation by Western blot, that both antibodies are specific
for MT1-MMP, it is striking that ab7 did label RGC
axons while ab8 did not. One could speculate that MT1-
MMP subspecies are present in different cell types/cell
compartments, resulting in differential labeling by these
antibodies due to their differential specificity/sensitivity
for certain subspecies of MT1-MMP.
Expression data about MT1-MMP in the retina is very
limited, especially in mice. One report, in which MT1-
MMP expression was studied in the retina of newborn
mice (P0) by means of in situ hybridization, described
MT1-MMP expression in the NFL [57]. Higher reso-
lution images and immunohistochemical double stain-
ings are necessary to determine whether MT1-MMP
mRNA was seen in axons and/or in Müller glia end feet
there. Moreover, in situ hybridization images shown in
this manuscript also revealed MT1-MMP mRNA ex-
pression in the photoreceptor layer (PRL). Likewise,
MT1-MMP expression was seen in the photoreceptor
inner and outer segments of human and equine retina,
respectively [58, 59]. Immunohistochemical staining for
MT1-MMP on rabbit retinal sections resulted in labeling
of the inner retinal layers [60], displaying high similarity
to the staining pattern of Müller glia end feet. On the
contrary, immunohistochemical stainings and in situ
hybridization experiments in human and monkey optic
nerves, did not reveal MT1-MMP expression in axons,
but even so in astrocytes [43, 44]. Taken together, the
data presented in this chapter are in line with the limited
expression data available in mouse and rabbit, but do
not correspond to the expression profile that was ob-
served in primates.
Remarkably, virtually nothing is known about the role
of MT1-MMP in the retina. Based on its spatial expres-
sion pattern described here, one could speculate that
MT1-MMP might be involved in maintaining axonal
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integrity and/or in glial reactivity. However there is no
concrete evidence to support these theories and further
studies exploring its function in the retina are urgently
needed.
Conclusions
In summary, the basal expression pattern of MMP-2, -3,
-9 and MT1-MMP was studied in the mouse retina by
means of immunohistochemical stainings and Western
blot. All four MMPs were found to be expressed in the
retina of healthy, adult mice. MMP-2 expression was
seen in Müller glia, predominantly in their end feet,
which is in line with available literature. MMP-3 expres-
sion was described for the first time in the retina, and
was observed in vesicle-like structures along the radial
fibers of Müller glia. MMP-9 expression has already ex-
tensively been studied but still discords exists about its
cellular source of expression. The data obtained in this
study corroborate that MMP-9 is expressed by microglia
and by a sparse subset of (apoptosing) RGCs. MT1-
MMP localization was for the first time studied in adult
mice and was found in RGC axons and Müller glia,
mimicking the MT1-MMP expression pattern seen in
rabbits and neonatal mice.
For each of the MMP antibodies, Western blots were
performed to evaluate their specificity and sensitivity.
Results indicated that the specificity of an antibody can-
not be taken for granted, and that immunostainings
should always be interpreted with caution. Nevertheless,
one antibody was selected for each MMP, based on its
staining pattern in WB. Notably, these Western blot ex-
periments further emphasized the complex regulation of
MMPs: pro-form versus active MMPs were seen, as well
as degradation products and homo- and heterodimers.
This adds an extra level of complexity to the interpret-
ation of immunohistochemical stainings and Western
blots, and, once again, stresses the importance of using
complementary sets of well-validated techniques to
evaluate MMP expression and activity.
Altogether, these data can be instrumental to study
MMP expression in mouse models of retinal pathologies.
Indeed, current literature about MMPs in the retina, and
their potential contribution to retinal pathologies, is very
limited. Nevertheless, the combined data from expres-
sion studies in glaucoma patients and animal models of
GON point to the involvement of MMPs during retinal
neurodegeneration. A first requisite for the disentangle-
ment of the exact role of MMPs in GONs, and other ret-
inal/ocular pathologies, is to assess whether MMP
expression in animal disease models corresponds to
what has been observed in clinical studies.
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